Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

295.37 +0.84 (+0.29%)
Streaming Delayed Price Updated: 9:34 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
47 48 Next >
Is Amgen Stock a Buy Now?
A recent analyst upgrade has boosted the stock. 
Via The Motley Fool
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Top Healthcare Stocks to Buy for the Long Haul
These biotech companies have a long ramp of revenue growth ahead. 
Via The Motley Fool
MarketBeat: Week in Review 10/10-10/14
A volatile week is ending with the market moving lower. Here are some of the stories the MarketBeat analysts were covering this week. 
Via MarketBeat
Exposures COVID-19
Expert Ratings for Amgen
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
Via Benzinga
Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
Shares of Amgen soared 5.72% Tuesday and added to those gains Wednesday. The gap-up followed a Morgan Stanley upgrade and increase to the price target. 
Via MarketBeat
Dividend Income Update September 2022
With the start of the final quarter of 2022, it’s time to take a look back at my previous month of dividend income. 
Via Talk Markets
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before. 
Via Investor's Business Daily
What 6 Analyst Ratings Have To Say About Amgen
Over the past 3 months, 6 analysts have published their opinion on Amgen (NASDAQ:AMGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Why Amgen Is Up More Than 6% Today
An upgrade highlights one of the more philosophical reasons you want to bet on this biopharma name right now. 
Via The Motley Fool
4 Biotech Stocks With Huge Incoming Catalysts
All four of these drugmakers are expecting important FDA approval decisions over the next few months. 
Via The Motley Fool
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Analyst Ratings for Amgen
Over the past 3 months, 5 analysts have published their opinion on Amgen (NASDAQ:AMGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity
One analyst says a coming-from-behind obesity player could differentiate itself. 
Via Investor's Business Daily
A Congressman Just Sold JPMorgan Stock Ahead Of Earnings: See Two Dividend Stocks He Is Also Trading
Congressman Earl Blumenauer (D-Ore.) has served as the U.S. Representative for Oregon's 3rd congressional district since 1996. 
Via Benzinga
DICE Therapeutics, Amgen And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly lower, with the Nasdaq dropping more than 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
Apple To $155? Plus Morgan Stanley Cuts Price Target On Zoom Video
Barclays cut the price target on Apple Inc. (NASDAQ: AAPL) from $169 to $155. Apple shares fell 0.4% to $139.93 in pre-market trading. 
Via Benzinga
US Buys $290M Anti-Radiation Drugs After Putin Ups Nuclear Threats
President Joe Biden has warned that the country may face nuclear Armageddon for the first time since the Cuban Missile Crisis of 1962. 
Via Benzinga
7 Value Stocks That Are Too Cheap to Ignore
With market and economic forces eschewing growth-focused companies, now may be the time to consider cheap value stocks to buy. 
Via InvestorPlace
2 Healthcare Stocks That Could Help Make You a Fortune
If given enough time, these two stocks can do the heavy lifting in building wealth for you. 
Via The Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.65% on an annualized basis producing an average annual return of 9.66%. Currently, Amgen has a market capitalization of... 
Via Benzinga
The Short List Of Dow Jones Stocks That Are Actually Up This Year: Hint — It's Very Short
The stock market has had a rough going for the first nine months of the year in 2022. All the major indexes are down year-to-date, including the Dow Jones Industrial Average. Here’s a look at the four... 
Via Benzinga
Warning! A Housing Market Crash Will Tank These 3 Stocks.
Don't be complacent about a potential black-swan event. A housing market crash would send these three stocks plunging. 
Via InvestorPlace
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. 
Via InvestorPlace
Costco Down After Earnings as Analysts Fret About Company Facing Higher Costs
(Friday Market Open) The end of the week isn’t bringing much relief for investors. 
Via Benzinga
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.43% on an annualized basis producing an average annual return of 9.79%. Currently, Amgen has a market capitalization of... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.